Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

American Journal of Cardiology

Volumn 90, Issue 10, 2002, Pages 1084-1091

  Gagné, Claude ^a   Bays, Harold E ^c   Weiss, Stuart R ^e   Mata, Pedro ^b   Quinto, Katherine ^d   Melino, Michael ^d   Cho, Meehyung ^d   Musliner, Thomas A ^d   Gumbiner, Barry ^d  

^a LAVAL UNIVERSITY   (Canada)

^b Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^c LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e RADIANT RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MYALGIA; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYNCOPE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUEBEC; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0037111890     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02774-1     Document Type: Article

References (26)

1. van Heek M., France C.F., Compton D.S., McLeod R.L., Yumibe N.P., Alton K.B., Sybertz E.J., Davis H.R. Jr. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 283:1997;157-163.
2. van Heek M., Farley C., Compton D.S., Hoos L., Alton K.B., Sybertz E.J., Davis H.R. Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 129:2000;1748-1754.
3. van Heek M., Farley C., Compton D., Hoos L., Davis H.R. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 134:2001;409-417.
4. Knopp R.H., Bays H., Manion C.V., Lipka L.J., Melani L., LeBeaut A.P., Suresh R., Veltri E.P., Ezetimibe Study Group . Effect of ezetimibe on serum concentrations of lipid-soluble vitamins. (abstr) Atherosclerosis. 2:(suppl):2001;90.
5. Zhu Y., Statkevich P., Maxwell S., Patrick J.E., Calzetta A., Kosoglou T., Cayen M.N., Batra V.K. The effect of gender on the pharmacokinetics of SCH 58235, a cholesterol absorption inhibitor (abstr). AAPS Pharmaceutical Science. 1999 AAPS Annual Meeting Supplement: 1999;S24. 1; Available at: http://www. pharmsci.org/scientificjournals/pharmsci/am_abstracts/1999/1623.htm.
6. Zhu Y., Statkevich P., Kosoglou T., Zambas D., Patrick J., Cayen M.N., Batra V. Effect of SCH 58235 on the activity of drug metabolizing enzymes in vivo. (abstr) Clin Pharmacol Ther. 67:2000;152.
7. Kosoglou T., Guillaume M., Sun S., Pember L.J.C., Reyderman L., Statkevich P., Cutler D.L., Veltri E.P., Affrime M.B. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe. (abstr) Atherosclerosis. 2:(suppl):2001;38.
8. Bauer K.S., Kosoglou T., Statkevich P., Calzetta A., Maxwell S.E., Patrick J.E., Batra V. Ezetimibe does not affect the pharmacokinetics or pharmacodynamics of warfarin. (abstr) Clin Pharmacol Ther. 69:2001;P5.
9. Kosoglou T., Meyer I., Musiol B., Anderson L., Reyderman L., Statkevich P., Cutler D.L., Veltri E.P., Affrime M.B. Pharmacodynamic interaction between fluvastatin and ezetimibe has favorable clinical implications. (abstr) Atherosclerosis. 2:(suppl):2001;89.
10. Statkevich P., Reyderman L., Kosoglou T., Woloj M., Maxwell S.E., Cutler D.L., Batra V., Kleinermans D. Ezetimibe does not affect the pharmacokinetics and pharmacodynamics of glipizide. (abstr) Clin Pharmacol Ther. 68:2001;P67.
11. Keung A.C.F., Kosoglou T., Statkevich P., Anderson L., Boutros T., Cutler D.L., Batra V., Sellers E.M. Ezetimibe does not affect the pharmacokinetics of oral contraceptives. (abstr) Clin Pharmacol Ther. 69:2001;P55.
12. Kosoglou T., Statkevich P., Bauer K.S., Cutler D.L., Maxwell S.E., Yang B., Soni P.P., Vatra V.K. zetimibe does not alter the pharmacokinetics and pharmacodynamics of digoxin (abstr). E. AAPS Pharmaceutical Science. 2001 AAPS Annual Meeting Supplement. 2001;3. Available at: http://www.aapspharmaceutica.com/search/abstract_view.asp?id=290.
13. Krishna G, Kosoglou T, Ezzet F, Pember L, Statkevich P, Boutros T, Maxwell SE, Basso L, Batra VK. Effect of cimetidine on the pharmacokinetics of ezetimibe (abstr). AAPS Pharmaceutical Science 2001 AAPS Annual Meeting Supplement. 2001;3. Available at: http://www.aapspharmaceutica.com/search/abstract_view.asp?id=304.
14. Dujovne C., Ettinger M.P., McNeer J.F., Lipka L.J., Lebeaut A.P., Suresh R., Veltri E.P. Ezetimibe, a selective cholesterol absorption inhibitor, improves plasma lipids in hypercholesterolemic patients. (abstr) Circulation. 104:(suppl II):2001;176.
15. Knopp R.H., Gitter H., Truitt T., Lipka L.J., LeBeaut A.P., Suresh R., Veltri E.P. Ezetimibe reduces low-density lipoprotein cholesterol results of a Phase III, randomized, double-blind, placebo-controlled trial . (abstr) Atherosclerosis. 2:(suppl):2001;38.
16. Davidson M., McGarry T., Bettis R., Melani L., Lipka L., LeBeaut A., Suresh R., Sun S., Veltri E., Ezetimibe Study Group . Ezetimibe co-administered with simvastatin in 668 patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl A):2002;226A-227A.
17. Ballantyne C., Houri J., Notarbartolo A., Melani L., Lipka L., LeBeaut A., Suresh R., Sun S., Veltri E., Ezetimibe Study Group . Ezetimibe co-administered with atorvastatin in 628 patients with primary hypercholesterolemia. J Am Coll Cardiol. 39:(suppl A):2002;227A.
18. NCEP Expert Panel . Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection evaluation, andtreatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 269:1993;3015-3023.
19. NCEP Expert Panel . Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
20. American Diabetes Association . Management of dyslipidemia in adults with diabetes. Diabetes Care. 21:1998;179-182.
21. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
22. Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 344:1994;1383-1389.
23. World Health Organization . Adverse Reaction Terminology. December 1999;. Available at http://www.who-umc.org/pdfs/ardguide.pdf.
24. NHLBI Obesity Education Expert Panel. Treatment guidelines. In: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, MD: National Institutes of Health/National Heart, Lung, and Blood Institute, 1998;98-4083:56-93.
25. Garnett W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm. 52:1995;1639-1645.
26. Omar M.A., Wilson J.P., Cox T.S. Rhabdomyolysis, and HMG-CoA reductase inhibitors. Ann Pharmacother. 35:2001;1096-1107.